Premium
Predictive Genetic Testing for Drug‐Induced Liver Injury: Considerations of Clinical Utility
Author(s) -
Alfirevic A,
Pirmohamed M
Publication year - 2012
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.2012.107
Subject(s) - drug , pharmacodynamics , liver injury , clinical pharmacology , pharmacology , medicine , human leukocyte antigen , genetic predisposition , genetic association , pharmacogenetics , genetic testing , pharmacokinetics , computational biology , bioinformatics , biology , immunology , genetics , single nucleotide polymorphism , genotype , gene , antigen , disease
Genetic predisposition to drug‐induced liver injury may be due to variation in both pharmacokinetic and pharmacodynamic pathways. Recent genome‐wide association studies have identified, in the human leukocyte antigen (HLA) alleles, strong genetic factors that predispose to liver injury on exposure to any of several drugs. Although the genetic associations have provided mechanistic insights, none has been developed as a predictive test. Further work in this area, in combination with other “‐omics” technologies, is needed to develop tests that are both clinically useful and cost‐effective. Clinical Pharmacology & Therapeutics (2012); 92 3, 376–380. doi: 10.1038/clpt.2012.107